AbstractThere is a need for new safe, effective and short-course treatments for leishmaniasis; one strategy is to use combination chemotherapy. Polymer–drug conjugates have shown promise for the delivery of anti-leishmanial agents such as amphotericin B. In this paper, we report on the preparation and biological evaluation of polymer–drug conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA), amphotericin B and alendronic acid. The combinatorial polymer–drug conjugates were effective anti-leishmanial agents in vitro and in vivo, but offered no advantage over the single poly(HPMA)–amphotericin B conjugates
Leishmaniasis is a life-threatening disease with a worldwide distribution and a huge impact especia...
There continues to be a need for an affordable and stable formulation of amphotericin B (AmB) to tre...
Visceral leishmaniasis is the second largest parasitic killer in the world (after malaria) with 59,0...
There is a need for new safe, effective and short-course treatments for leishmaniasis; one strategy ...
AbstractThere is a need for new safe, effective and short-course treatments for leishmaniasis; one s...
Leishmaniasis is a major health problem in many parts of the world, caused by various species of Lei...
The present work describes the synthesis, characterization, and biological evaluation of targetable ...
AbstractLeishmaniasis is a major health problem in many parts of the world, caused by various specie...
Leishmaniasis is a major health problem in many parts of the world, caused by various species of Lei...
The Supporting Information is available free of charge at: https://pubs.acs.org/doi/10.1021/acs.biom...
There is an urgent need for a safe, low cost, tropical climate stable and simply reconstituted repla...
A challenge to successful chemotherapy of visceral leishmaniasis is the dose-limiting toxicity of an...
A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develo...
Amphotericin B (AmB) is used to treat a neglected disease called visceral leishmaniasis (VL). We hyp...
A noncovalent, water-soluble complex of amphotericin B (AMB) and poly(α-glutamic acid) (PGA), with A...
Leishmaniasis is a life-threatening disease with a worldwide distribution and a huge impact especia...
There continues to be a need for an affordable and stable formulation of amphotericin B (AmB) to tre...
Visceral leishmaniasis is the second largest parasitic killer in the world (after malaria) with 59,0...
There is a need for new safe, effective and short-course treatments for leishmaniasis; one strategy ...
AbstractThere is a need for new safe, effective and short-course treatments for leishmaniasis; one s...
Leishmaniasis is a major health problem in many parts of the world, caused by various species of Lei...
The present work describes the synthesis, characterization, and biological evaluation of targetable ...
AbstractLeishmaniasis is a major health problem in many parts of the world, caused by various specie...
Leishmaniasis is a major health problem in many parts of the world, caused by various species of Lei...
The Supporting Information is available free of charge at: https://pubs.acs.org/doi/10.1021/acs.biom...
There is an urgent need for a safe, low cost, tropical climate stable and simply reconstituted repla...
A challenge to successful chemotherapy of visceral leishmaniasis is the dose-limiting toxicity of an...
A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develo...
Amphotericin B (AmB) is used to treat a neglected disease called visceral leishmaniasis (VL). We hyp...
A noncovalent, water-soluble complex of amphotericin B (AMB) and poly(α-glutamic acid) (PGA), with A...
Leishmaniasis is a life-threatening disease with a worldwide distribution and a huge impact especia...
There continues to be a need for an affordable and stable formulation of amphotericin B (AmB) to tre...
Visceral leishmaniasis is the second largest parasitic killer in the world (after malaria) with 59,0...